Alphatec (NASDAQ:ATEC) Trading 13.1% Higher - Still a Buy?

Key Points

• 13.1% intraday surge: Alphatec shares jumped about $7.91 on heavy volume after several firms (including J.P. Morgan and HC Wainwright) issued buy ratings and the company reported 21% case‑volume growth in Q1.
• Financial and guidance weakness: The company missed Q1 EPS (reported ($0.22) vs. ($0.01) expected) and trimmed its full‑year revenue outlook, prompting analyst price‑target cuts and prior share declines.
• Heightened downside risks: Recent sizable insider and institutional selling plus multiple shareholder‑law‑firm investigations raise litigation and additional sell‑pressure concerns for the stock.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report)'s share price traded up 13.1% during trading on Thursday . The stock traded as high as $7.79 and last traded at $7.9080. 3,433,228 shares traded hands during mid-day trading, an increase of 7% from the average session volume of 3,211,255 shares. The stock had previously closed at $6.99.

Key Alphatec News

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: J.P. Morgan published a buy on ATEC, providing institutional-level support that can attract buyers. Article Title
• Positive Sentiment: HC Wainwright reaffirmed its buy rating and keeps a $24 price target, signaling conviction from a growth-oriented analyst. Article Title
• Positive Sentiment: Operationally, Alphatec reported 21% case-volume growth in Q1 — a concrete demand signal that supports revenue recovery potential. Article Title
• Neutral Sentiment: TD Cowen cut its price target to $11 but maintained a “buy,” which reduces the upside case but leaves institutional support intact. Article Title
• Neutral Sentiment: Wells Fargo lowered its target from $28 to $14 but kept an “overweight” rating — another signal that expectations have been reset but sentiment remains constructive. Article Title
• Negative Sentiment: JPMorgan cut its price target to $16 (from $24), trimming institutional upside and contributing to recent selling pressure. Article Title
• Negative Sentiment: Needham lowered its target from $25 to $14, another analyst cut that reduces headline upside and investor confidence. Article Title
• Negative Sentiment: MarketWatch reports shares plunged after Alphatec trimmed its full‑year revenue outlook — guidance cuts are the primary negative catalyst behind recent declines. Article Title
• Negative Sentiment: Several firms/funds have been selling ATEC (including Lisanti’s $5.4M unload and another reported $18M sale), increasing supply and downward pressure. Article Title Article Title
• Negative Sentiment: Legal risk: multiple shareholder‑law‑firms (Ademi LLP, Johnson Fistel) have opened investigations into possible securities claims, which raises litigation and disclosure risk. Article Title Article Title

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Stifel Nicolaus dropped their price objective on Alphatec from $24.00 to $20.00 and set a "buy" rating on the stock in a research note on Monday, March 9th. Wall Street Zen upgraded Alphatec from a "hold" rating to a "buy" rating in a research note on Saturday, January 31st. Weiss Ratings upgraded Alphatec from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday. Lake Street Capital reiterated a "buy" rating and issued a $15.00 price objective on shares of Alphatec in a research note on Wednesday. Finally, Wells Fargo & Company dropped their price objective on Alphatec from $28.00 to $14.00 and set an "overweight" rating on the stock in a research note on Thursday. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $18.58.

Alphatec Trading Up 10.9%

The stock has a market cap of $1.19 billion, a PE ratio of -9.45 and a beta of 0.96. The firm has a 50-day simple moving average of $11.60 and a 200-day simple moving average of $15.90. The company has a quick ratio of 1.28, a current ratio of 2.06 and a debt-to-equity ratio of 40.35.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Tuesday, May 5th. The medical technology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.21). The company had revenue of $192.11 million for the quarter, compared to analysts' expectations of $197.51 million. Alphatec had a negative return on equity of 788.36% and a negative net margin of 15.93%.The company's revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.35) EPS. Equities analysts forecast that Alphatec Holdings, Inc. will post -0.28 earnings per share for the current year.

Insider Activity

In other news, COO Scott Lish sold 260,535 shares of the company's stock in a transaction on Friday, March 13th. The shares were sold at an average price of $12.30, for a total value of $3,204,580.50. Following the transaction, the chief operating officer owned 815,704 shares of the company's stock, valued at approximately $10,033,159.20. This represents a 24.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Tyson Eliot Marshall sold 88,835 shares of the company's stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $12.49, for a total transaction of $1,109,549.15. Following the completion of the transaction, the general counsel directly owned 559,459 shares in the company, valued at approximately $6,987,642.91. The trade was a 13.70% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 629,189 shares of company stock worth $7,801,589. Company insiders own 20.90% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ATEC. Summit Securities Group LLC bought a new position in shares of Alphatec in the first quarter worth $29,000. Aster Capital Management DIFC Ltd bought a new position in shares of Alphatec in the third quarter worth $34,000. Osterweis Capital Management Inc. bought a new position in shares of Alphatec in the second quarter worth $37,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Alphatec by 157.1% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company's stock worth $54,000 after purchasing an additional 1,571 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Alphatec in the third quarter worth $73,000. Institutional investors own 66.35% of the company's stock.

About Alphatec

Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.